SavedAdd your journal

Journals / Gülhane Tıp Dergisi / 2019 / Cilt: 61 - Sayı: 1

A rare cause of reactive arthritis etiology: Bacillus calmette-guerin immunotherapy

Emre TEKGÖZ
MUHAMMET ÇINAR
SEDAT YILMAZ
Pages
28–29
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Here in, we discussed a case of reactive arthritis developed after intravesical Bacillus Calmette Guerin immunotherapy used as adjuvant treatment for bladder cancer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Reactive arthritis belongs to the spondyloarthritis group that manifests up to 6 weeks after a gastrointestinal or genitourinary infection.
📊
Key Findings & Data:Usually presents with asymmetric monooligo arthritis on the lower extremity and accompanying extraarticular findings can often be observed on follow-up.
💡
Conclusion & Impact:Here in, we discussed a case of reactive arthritis developed after intravesical Bacillus Calmette Guerin immunotherapy used as adjuvant treatment for bladder cancer.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Reactive arthritis belongs to the spondyloarthritis group that manifests up to 6 weeks after a gastrointestinal or genitourinary infection. Usually presents with asymmetric monooligo arthritis on the lower extremity and accompanying extraarticular findings can often be observed on follow-up. Here in, we discussed a case of reactive arthritis developed after intravesical Bacillus Calmette Guerin immunotherapy used as adjuvant treatment for bladder cancer.

🔖

Cite This Article

TEKGÖZ, E., ÇINAR, M., YILMAZ, S. (2019). A rare cause of reactive arthritis etiology: Bacillus calmette-guerin immunotherapy. Gülhane Tıp Dergisi, Cilt: 61 - Sayı: 1, 28–29. https://ajindex.com/articles/162600

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Parker CT, Thomas D. Reiter’s syndrome and reactive arthritis. J Am Osteopath 2000; 100(2):101–104
  2. Stavropoulos PG, Soura E, Kanelleas A, et al. Reactive arthritis. J Eur Acad Dermatol Venereol 2015; 29(3): 415-424
  3. Hannu T, Mattila L, Siitonen A, Leirisalo-Repo M. Reactive arthritis attributable to Shigella infection: a clinical and epidemiological nationwide study. Annals of the rheumatic diseases 2005; 64(4): 594-598
  4. Aho K, Ahvonen P, Lassus A, Sievers K, Tiilikainen A. HL-A antigen 27 and reactive arthritis. The Lancet 1973; 302(7821): 157
  5. Kim PS, Klausmeier TL, Orr DP. Reactive arthritis: a review. Journal of Adolescent Health 2009; 44(4): 309-315
  6. Colmegna I, Cuchacovich R, Espinoza LR. HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations. Clin Microbiol Rev 2004; 17(2): 348–369
  7. Wu IB, Schwartz RA. Reiter’s syndrome: the classic triad and more. J Am Acad Dermatol 2008; 59(1): 113–121
  8. Schneider JM, Matthews JH, Graham BS. Reiter’s syndrome. Cutis 2003; 71(3): 198–200
  9. Sieper J. Pathogenesis of reactive arthritis. Curr Rheumatol Rep 2001; 3(5): 412–418
  10. Donin NM, Lenis AT, Holden S, et al. Immunotherapy for the Treatment of Urothelial Carcinoma. J Urol 2017;197(1):14-22.